Advertisement
Advertisement
U.S. markets open in 1 hour 44 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Artelo Biosciences, Inc. (ARTL)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.4500-0.0400 (-1.15%)
At close: 04:00PM EDT
3.3100 -0.14 (-4.06%)
Pre-Market: 04:00AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Previous Close3.4900
Open3.4473
Bid3.2800 x 800
Ask3.5900 x 1800
Day's Range3.3900 - 3.5000
52 Week Range3.1100 - 19.8000
Volume10,919
Avg. Volume337,140
Market Cap9.797M
Beta (5Y Monthly)1.30
PE Ratio (TTM)N/A
EPS (TTM)-0.3160
Earnings DateNov 11, 2022 - Nov 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est41.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ARTL

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Artelo Biosciences, Inc.
    Daily – Vickers Top Buyers & Sellers for 09/15/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    18 days agoArgus Research
View more
  • GlobeNewswire

    Artelo Biosciences to Present at the 2022 Ladenburg Thalmann Healthcare Conference on September 29th

    SOLANA BEACH, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that it will be presenting at the 2022 Ladenburg Thalmann Healthcare Conference being held on September 29, 2022 at the Sofitel Hotel in New York City. Gregory D. Gorgas, Chief Executive Officer of Artelo, is sc

  • GlobeNewswire

    Artelo Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference

    SOLANA BEACH, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that Gregory D. Gorgas, Chief Executive Officer of Artelo, will be presenting at the H.C. Wainwright 24th Annual Global Investment Conference which is being held September 12 - 14, 2022. The event will include v

  • GlobeNewswire

    Artelo Biosciences Reports Positive Pre-Clinical Results with its Novel Inhibitor to Fatty Acid Binding Protein 5

    Recently Published Findings Support Further Development in Anxiety-Related DisordersSOLANA BEACH, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced publication of pre-clinical results indicating a novel fatty acid binding protein 5 (FABP5) inhibitor from the Company’s FABP in

Advertisement
Advertisement